Bone Tissue Engineering Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia. Osteophytes are the most remarkable and consistently distinct feature of osteoarthritis (OA). Their formation may be related to pluripotential cells in the periosteum responding to stimulus during OA. This study aimed to isolate stem cells from osteophyte tissues, and characterise their phenotype, proliferation and differentiation potential, and immuno-modulatory properties. Osteophyte derived cells were isolated from five osteophyte tissue samples collected during knee replacement surgery. These cells were characterised by the expression of cell surface antigens, differentiation potential into mesenchymal lineages, growth kinetics and modulation of allo-immune responses. Multipotential stem cells (MSCs) were identified from all osteophyte samples namely osteophyte derived MSCs (oMSCs). The surface antigen expression of oMSCs was consistent with that of mesenchymal stem cells, such as lacking the haematopoietic and common leukocyte markers (CD34, CD45) while expressing those related to adhesion (CD29, CD166, CD44) and stem cells (CD90, CD105, CD73). The longevity of oMSCs in culture was superior to that of bone marrow derived MSC (bMSCs), and they readily differentiated into tissues of the mesenchymal lineages. oMSCs also demonstrated the ability to suppress allogeneic T-cell proliferation, which was associated with the expression of tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO). Our results showed that osteophyte derived cells had similar properties to mesenchymal stem cells in the expression of antigen phenotype, differential potential and suppression of allo-immune response. Furthermore, when compared to bMSCs, oMSCs maintained a higher proliferative capacity, which may offer an alternative source for therapeutic stem cell based tissue regeneration.
We describe the clinical and radiological results of thirty eight consecutive total hip replacements, using the JRI Furlong Hydroxyapatite ceramic coated femoral component (JRI Instrumentation Ltd, London, UK) in patients under the age of 50 at the time of surgery. The mean age at the time of operation was 42 years (range 22 to 49 years). The average length of follow up was 10 years (range 63 to 170 months). All patients receiving a Furlong HAC THR were included regardless of their primary aetiology. These included patients on whom previous hip joint surgery had taken place. The mean Harris hip score improved from 44 pre-operatively to 92 at the latest post-operative review. The mean WOMAC and Oxford scores at the latest review for this study were 29 and 16 respectively. Using the Charnley modification of the Merle d’Aubign_ and Postel hip score, at the latest follow up the mean scores were as follows: Pain 5.37, Function 5.47, and Range of Motion 5.71. The mean pain visual analogue score was 1.1 and 94% of patients returned to outdoor activities or sports. There were no reports of thigh pain at any review. There was no loss to follow-up. There were no revisions of any femoral component. Radiological review of the femoral components revealed no continuous or progressive radiolucent lines around the stem. No osteolysis was noted. Using revision or impending revision as the end point at 12 years the cumulative survival for the stem was 100% (95% CI 89 to 100). We present excellent clinical, radiological and survivrship results with the use of HAC components in young, active patients with varying primary pathology, after ten years use.
Limb lengthening by callus distraction and external fixation has a high rate of complications. We describe our experience using an intramedullary nail (Fitbone) which contains a motorised and programmable sliding mechanism for limb lengthening and bone transport. Between 2001 and 2004 we lengthened 13 femora and 11 tibiae in ten patients (seven men and three women) with a mean age of 32 years (21 to 47) using this nail. The indications for operation were short stature in six patients and developmental or acquired disorders in the rest. The mean lengthening achieved was 40 mm (27 to 60). The mean length of stay in hospital was seven days (5 to 9). The mean healing index was 35 days/cm (18.8 to 70.9). There were no cases of implant-related infection or malunion.
We describe the clinical and radiological results of 120 consecutive revision hip replacements in 107 patients, using a titanium alloy femoral component fully coated with Hydroxyapatite ceramic (HAC). The mean age at operation was 71 years (range 36 to 92). The average length of follow up was 8.0 years (range 5.0 to 12.4). All patients receiving a JRI Furlong HAC coated femoral component (JRI Instrumentation Ltd, London, UK) with a minimum follow up of 5 years were included. These included patients on whom previous revision hip joint surgery had taken place. Patients were independently reviewed and scored using the Harris Hip Score (HHS), the Charnley modification of the Merle d’Aubigne and Postel Score (MDP), and The Western Ontario and McMaster Universities Osteoarthritis index (WOMAC). Radiographs were assessed by three reviewers (blinded to clinical details) for new bone formation, osteolysis, osteointegration and radiolucent lines in each Gruen Zone. The mean Harris hip score was 85.8 (range 42 to 100) at the latest post-operative review. The mean WOMAC and MDP scores were 34.5 and 14.8 respectively. The mean pain visual analogue score (range 0 to 10) was 1.2 overall and 0.5 specifically for mid-thigh pain. There were no revisions of any femoral component for aseptic loosening. There were four stem re-revisions (3 cases of infection, 1 recurrent dislocation). Radiological review of all femoral components, including the four mentioned, revealed stable bone ingrowth with no new radiolucent lines in any zone. Using revision or impending revision for aseptic loosening as the end point, at 10 years the cumulative survival for the stem was 100% (95% CI 94 to 100). We present excellent medium to long term clinical, radiological and survivorship results with the use of a fully HAC coated titanium stem in revision hip surgery.
We describe the clinical and radiological results of 120 consecutive revision hip replacements in 107 patients, using the JRI Furlong hydroxyapatite-ceramic-coated femoral component. The mean age of the patients at operation was 71 years (36 to 92) and the mean length of follow-up 8.0 years (5.0 to 12.4). We included patients on whom previous revision hip surgery had taken place. The patients were independently reviewed and scored using the Harris hip score, the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) and the Charnley modification of the Merle d’Aubigné and Postel score. Radiographs were assessed by three reviewers for the formation of new bone, osteolysis, osseointegration and radiolucent lines in each Gruen zone. The mean Harris hip score was 85.8 (42 to 100) at the latest post-operative review. The mean WOMAC and Merle d’Aubigné and Postel scores were 34.5 and 14.8, respectively. The mean visual analogue score for pain (possible range 0 to 10) was 1.2 overall, but 0.5 specifically for mid-thigh pain. There were no revisions of the femoral component for aseptic loosening. There were four re-revisions, three for infection and one for recurrent dislocation. Radiological review of all the femoral components, including the four re-revisions showed stable bony ingrowth and no new radiolucent lines in any zone. Using revision or impending revision for aseptic loosening as an end-point, the cumulative survival of the femoral component at ten years was 100% (95% confidence interval 94 to 100). We present excellent medium- to long-term clinical, radiological and survivorship results with the fully hydroxyapatite-ceramic-coated femoral component in revision hip surgery.
We describe the clinical and radiological results of 38 total hip replacements (THR) using the JRI Furlong hydroxyapatite-ceramic (HAC)-coated femoral component in patients younger than 50 years. The mean age at the time of operation was 42 years (22 to 49) and the mean length of follow-up was ten years (63 to 170 months). All patients receiving a Furlong HAC THR were entered into the study regardless of the primary pathology including patients who had undergone previous hip surgery. The mean Harris hip score improved from 44 before operation to 92 at the last postoperative review. After 12 years the cumulative surivival for the stem was 100% (95% confidence interval 89 to 100). No femoral component was revised. Our results show that the Furlong HAC implant gives excellent long-term results in young patients with high demands.
We reviewed 64 anterolateral decompressions performed on 63 patients with tuberculosis of the dorsal spine (D1 to L1). The mean age of the patients was 35 years (9 to 73) with no gender preponderance. All patients had severe paraplegia (two cases grade III, 61 cases grade IV). The mean number of vertebral bodies affected was 2.6; the mean pre-treatment kyphosis was 24.8° (7 to 84). An average of 2.9 ribs were removed in the course of 64 procedures. The mean time taken at surgery was 2.45 hours when two ribs were removed and 3.15 hours when three ribs were removed. Twelve patients (19%) showed signs of neurological recovery within seven days, 33 patients (52%) within one month and 12 patients (19%) after two months; but six patients (10%) showed no neurological recovery. Forty patients were followed up for more than two years. In 34 (85%) of these patients there was no significant change in the kyphotic deformity; two patients (5%) showed an increase of more than 20°.
Tibialis posterior tendon (TPT) dysfunction is a disorder of unknown aetiology. Trauma, inflammatory processes, anatomical abnormalities and iatrogenic factors have all been implicated as causative mechanisms. The condition presents with pain and swelling around the medial malleolus. The pain is characteristically worse on exercise and relieved by elevation. The disorder has been classified by Johnson and Strom (1989); stage I is characterized by pain around the medial malleolus and mild weakness of single heel raising. Without treatment the condition may progress to a fixed valgus deformity along with pes planus.
To assess the outcome of surgical decompression of stage I TPT dysfunction.
Ten cases were identified, operated on by a single surgeon over a three-year period. The patients were assessed in a dedicated clinic by administration of a questionnaire and by clinical examination.
Nine patients with an average age of 30 years (13–51) agreed to participate in the study. Six of the nine patients recalled a sporting injury to the ankle prior to onset of symptoms. Eight of these of patients underwent a course of physiotherapy prior to surgery. After decompression all patients reported reduction of pain as measured using a visual analogue scale, with five patients reporting complete resolution of pain. Patients experienced relief of pain on average four weeks (1.5–6) after surgery. All patients were able to return to work and normal leisure activities after appropriate rehabilitation.
Decompression of the tibialis posterior tendon in stage I dysfunction leads to pain relief and enables an early return to normal activities. Therefore surgical decompression of the tibialis posterior tendon may be considered in cases of stage I dysfunction which are refractory to conservative measures, particularly in young and active patients.